Sabbagh Ali, Mohamad Osama, Lichter Katie E, Hope Thomas A
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94158, USA.
Department of Urology, University of California San Francisco, San Francisco, CA 94143, USA.
Cancers (Basel). 2022 Dec 15;14(24):6194. doi: 10.3390/cancers14246194.
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans have higher sensitivity and specificity for detecting lymph nodes or metastatic disease relative to conventional imaging in prostate cancer staging. Since its FDA approval and incorporation into treatment guidelines, the use of PSMA PET has increased in patients undergoing initial staging, those with recurrence after initial definitive treatment, and patients with metastatic disease. Although the early detection of metastatic lesions is changing disease management, it is unclear whether this impact on management translates into clinical benefit. This review will summarize evidence pertaining to the change in patient management due to PSMA PET use and will discuss the implications of PSMA PET on treatment decisions in prostate cancer, particularly in the settings of biochemical recurrence and metachronous oligometastatic disease.
相对于传统成像技术，前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）在前列腺癌分期中检测淋巴结或转移病灶时具有更高的敏感性和特异性。自其获得美国食品药品监督管理局（FDA）批准并纳入治疗指南以来，PSMA PET在接受初始分期的患者、初始确定性治疗后复发的患者以及转移性疾病患者中的使用有所增加。尽管转移性病变的早期检测正在改变疾病管理方式，但尚不清楚这种对管理的影响是否转化为临床获益。本综述将总结与使用PSMA PET导致的患者管理变化相关的证据，并将讨论PSMA PET对前列腺癌治疗决策的影响，特别是在生化复发和异时性寡转移疾病的情况下。
Zotero 插件